Single Dose FSH-GEX™ in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiple Dose FSH-GEX(TM) in Healthy Volunteers

NCT01477073

Female Infertility

COMPLETED PHASE1

Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®

NCT01794208

Infertility

COMPLETED PHASE2

Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF

NCT01798836

Infertility

TERMINATED PHASE2/PHASE3

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

NCT00417066

Infertility Premature Ovarian Failure

COMPLETED PHASE4

Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality

NCT03139474

Infertility, Female

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy pituitary-suppressed female subjects received FSH-GEX™ (25, 75, 150 and 300 IU) in three of four possible ascending doses or one dose of two comparators (Bravelle® and Gonal-f®) and placebo in random order. The study consisted of three separate treatment periods. During each treatment period the subject received one single dose via a subcutaneous injection in the lower abdominal wall.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Inclusion Criteria

1. Female subjects from 18-40 years of age.
2. Subjects must be in good health.
3. Subjects must be willing to use additional non-hormonal contraception
4. Subjects must have used a combined oral contraceptive (COC) for at least one cycle.
5. Vital signs which are within the following ranges at baseline measurements: systolic blood pressure of 90-140 mmHg, diastolic blood pressure of 50-90 mmHg and pulse rate of 40 - 100 bpm.
6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.0 kg/m\^2 at baseline measurements.
7. Able to provide written informed consent prior to study participation.
8. Able to communicate well with the investigator and to understand and comply with the requirements of the study.

Exclusion Criteria

1. Smokers of more than 10 cigarettes per day.
2. Average daily intake of more than 3 units of alcohol per day or an average weekly intake of more than 21 units alcohol.
3. Use of any prescription drug or ove the counter medication from screening until the end-of-study visit, without prior approval of the investigator.
4. Any drugs thay may reduce the effectiveness of COC from screening until the end-of-study visit.
5. Any follicle-stimulating hormone (FSH) preparation within 90 days prior to screening.
6. Administration of any investigational product or use of any investigational device within 30 days prior to screening.
7. Donation or loss of 500 mL or more blood within 90 days prior to first FSH-GEX™ dosing.
8. History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
9. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to any of the study drugs.
10. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of drugs or which may jeopardize the subject in case of participation in the study.
11. History or presence of any malignancy.
12. Determined or suspected pregnancy.
13. Breast feeding women.
14. History of (or current) endocrine abnormalities.
15. Contraindication for the use of oral contraceptives.
16. Contraindication for the use of follitropin alfa, FSH or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin; ovarian, uterine, or mammary carcinoma).
17. Porphyria or family history of porphyria.
18. History of ovarian surgery.
19. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound investigation.
20. An abnormal cervical smear.
21. History or presence of an immune-compromising disease, or a positive human immunodeficiency virus (HIV) test result in the past or at the screening visit.
22. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at the screening visit.
23. History of drug or alcohol abuse within the 12 months prior to the screening visit or evidence of such abuse.
24. Planned surgery or hospitalization during the period of the study.
25. Concurrent participation or participation within 30 days before screening in another clinical trial, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study.
26. Injection of one or more doses of any depot contraceptive drug /drug combination or hormonal implants \<= 10 months prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes